UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

  Date of Report (Date of earliest event reported) August 1, 2019 

100 – 740 McCurdy Road, Kelowna, BC Canada		V1X 2P7
(Address of principal executive offices)		(Zip Code)

 Registrant’s telephone number, including area code (250) 765-6424 

 N/A 

(Former name or former address, if changed since last report.) 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 7.01 Regulation FD Disclosure 

On August 1, 2019 (the “Effective Date”) Lexaria Bioscience Corp. (“Lexaria”) retained Integra Consulting Group LLC (“Integra”), an arm’s length entity, to provide investor relations services in compliance with regulatory guidelines. Integra is a California-based firm that provides a variety of services, including capital market services and investor relations services. The engagement of Integra will be for an initial term of six months (the “Initial Term”) which is automatically renewed for an additional six month term ending on July 31, 2020, unless terminated earlier by either party. It is anticipated that Integra will assist Lexaria with developing its US capital markets strategy and with communicating information and maintaining public awareness of Lexaria to shareholders, broker-dealers and the financial community. Lexaria will compensate Integra US$12,500 monthly for the provision of its services and will issue Integra 150,000 voting common shares in the authorized share capital of Lexaria within ten business days of the Effective Date at a deemed price of US$0.69 and, provided that Lexaria does not terminate the engagement of Integra, subsequent to the completion of the Initial Term, Lexaria shall issue Integra a further 180,000 voting common shares of its authorized share capital at a deemed price per share equal in value to the fair market price of Lexaria’s securities on the day prior to the date of issuance.

All shares issued by Lexaria shall bear a six month hold period and shall also contain the restrictive US legends as prescribed by US securities laws.

Lexaria also has summarized its current active licenses as follows:

Year to date 2019, Lexaria has announced:

Lexaria now has 9 corporate licensees who are developing innovative beverages, edibles and oral products with their 11 licenses using the Company’s fully patented DehydraTECH absorption technology:

Lexaria credits its recent commercial success mainly to its ever-growing body of scientific results evidencing the superior capabilities and power of its patented technologies. Recent 2019 technological advancements are the result of one of the industry’s most focused and productive R&D programs and hold promise for even higher levels of performance from new DehydraTECH innovations with even faster drug delivery into blood plasma and across the blood-brain-barrier.

In one recent animal study, as earlier announced, Lexaria’s latest patent-pending formulations delivered more than 1,900% more CBD into brain tissue than generic industry formulations and achieved peak blood levels more than 800% greater than those of concentration matched controls. In that same animal study, detection of CBD in the bloodstream began in as little as 2 minutes after dosing and peaked in as little as 45 minutes after dosing providing additional support that DehydraTECH enables rapid onset and offset in line with consumer preferences.

*Note 1: The license with Altria Ventures Inc is with Lexaria Nicotine LLC, a separate business division of Lexaria Bioscience Corp.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3